



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



COVID-19: Important Updates and Developments
Edited by Franco Rongioletti, MD, and Leonard J. Hoenig, MD

Dermatologic reactions to disinfectant use during the COVID-19 pandemic



Choon Fu Goh, RPh, PhD^{a,*}, Long Chiau Ming, RPh, PhD^b, Li Ching Wong, BS^a

^a*Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia*

^b*PAP Rashidah Sa'adatulk Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei Darussalam*

Abstract Infection preventive practice of using disinfectants against SARS-CoV-2 has become the new normal due to the COVID-19 pandemic. Although disinfectants may not be applied directly to the human body, it remains at high risk of exposure including close skin contact on disinfected surfaces or during handling. This dermal contact, on a regular basis, can induce hazardous skin reactions like irritation, inflammation, and burning in severe conditions. Disinfectants are germicide chemicals that can penetrate the skin and create skin reactions that are usually regarded as irritant and allergic contact dermatitis. More importantly, disinfectants can react with skin components (proteins and lipids) to facilitate their skin penetration and disrupt the skin barrier function. Whereas the antimicrobial actions of disinfectants are well understood, much less is known regarding their dermatologic reactions, including but not limited to irritation and hypersensitivity. We reviewed the skin reactions created by those disinfectants against SARS-CoV-2 approved by the European Chemical Agency and the US Environmental Protection Agency.

© 2020 Elsevier Inc. All rights reserved.

Introduction

The emergence of a novel coronavirus (SARS-CoV-2) at the end of 2019 was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020.¹ The alarming situation has triggered the practice of preventive actions that include the use of various disinfectants to sanitize the environment and to reduce the spread of infections. Owing to unawareness and inadequate experience in handling disinfectants among the public, this may cause an inappropriate use of disinfectants, which can create untoward events. Our skin is, thus, at risk of exposure to disinfectants, especially

during handling, storage, and application. Even though direct contact with disinfectants may not be often established, the risk of skin contact to the chemical residuals on disinfected surfaces remains high, especially when disinfectant use has become a routine practice.

Disinfectants are small and moderately lipophilic molecules (molecular weight <500 Da and log *P* ~1 to 4), which can penetrate the skin to induce a direct skin reaction. Skin reactions to various disinfectants can be wide, ranging from inflammation, lichenification, to discoloration, and even necrosis. Disinfectants are germicidal by definition and can react with epidermal keratin filaments and lipids, similar to reactions created by many antimicrobials to the lipid membrane and protein structure of microorganisms. These actions can facilitate skin penetration of chemicals into the deeper skin layers to aggravate any adverse reactions.

* Corresponding author.

E-mail addresses: choonfugoh@usm.my (C.F. Goh),
long.ming@ubd.edu.bn (L.C. Ming), lichingwong@student.usm.my
(L.C. Wong).

Most disinfectants can be regarded as potential skin irritants and/or sensitizers (allergens), including those indicated for human hygiene, such as alcohols and peroxygen compounds.² In response to external stimuli such as disinfectants, the skin immune system can react by secreting a range of pro-inflammatory mediators, including cytokines and chemokines, especially from keratinocytes, T cells, and dermal fibroblasts.^{3,4} They can create irritant (ICD) or allergic contact dermatitis (ACD).⁵ ICD is a nonspecific inflammatory response triggered by innate immune system due to toxic effects on the skin cells.⁵ While ACD is considered a delayed hypersensitivity response, where skin inflammation is mediated by antigen-specific T cells (adaptive immunity). The inflammation is not directly caused by the chemicals but rather the response of T cells to the haptenized protein.⁵

We have provided a comprehensive summary of dermatologic reactions due to the exposure of disinfectants. The data on percutaneous penetration and interactions with skin components in facilitating skin penetration are also highlighted. We have included only the disinfectants commonly found in consumer products from the lists of disinfectants approved by (1) the European Chemical Agency⁶ and (2) the US Environmental Protection Agency⁷ for use against SARS-CoV-2, where these disinfectants have demonstrated efficacy against a harder-to-kill virus

or another type of human coronavirus similar to SARS-CoV-2.

Classification of disinfectants

Table 1 shows the list of disinfectants commonly found in consumer products based on the various chemical classes and their examples and have included adverse reactions associated with the use of disinfectants and their skin penetration ability in Tables 2 and 3.

Alcohols

WHO recommends the use of alcohols, namely, ethanol (80%v/v) and isopropanol (75%v/v) in handrubs.⁸ Percutaneous penetration of both alcohols is generally low even with extensive use.^{9–11} They may create both ICD and ACD.^{8,12} This could be related to the solvent effect on skin components (Table 2) or preirritated skin with disrupted skin barrier.¹³ Because isopropanol is more irritating than ethanol,¹⁴ emollients, such as glycerol or propylene glycol, may be added to hand preparations.^{15–17} Allergic reactions, including contact urticarial, have been reported.^{18–20} The triggers may be due to impurities, aldehyde metabolites, or fragrances in the product.^{19,21}

Table 1 Classification of disinfectants and related examples

Classification	Examples
Alcohols	Ethanol, isopropanol
Aldehydes	Glutaraldehyde
Bases	<i>Oxides/hydroxides</i> Calcium dihydroxide, calcium hydroxide, calcium magnesium oxide, calcium magnesium tetrahydroxide, calcium oxide <i>Carbonates</i> Sodium carbonate, sodium carbonate peroxyhydrate, ammonium bicarbonate, ammonium carbonate
Biguanides	Polyhexamethylene biguanide hydrochloride (polyhexanide)
Chlorine and chlorine compounds	Chlorine dioxide, hydrochloric acid, hypochlorous acid, sodium chlorite, sodium hypochlorite, sodium dichloro-S-triazinetriene (sodium dichloroisocyanurate)
Glycols	Triethylene glycol, 1,2-hexanediol
Iodophors	Polyvinylpyrrolidone iodine
Metal ions	Silver ions, copper ions (copper sulfate pentahydrate)
Organic acids	<i>α-Hydroxy acids</i> Citric acid, glycolic acid, lactic acid <i>Fatty acids</i> Caprylic acid (octanoic acid), pelargonic acid (nonanoic acid)
Peroxygen compounds	Hydrogen peroxide, peroxyacetic acid (peracetic acid), potassium peroxymonosulfate
Phenolic compounds	Ortho-phenylphenol, ortho-benzyl-para-chlorophenol, thymol, chlorocresol
Surfactants	<i>Anionic surfactants</i> Dodecylbenzenesulfonic acid <i>Cationic surfactants/quaternary ammonium compounds</i> Old generation: benzalkonium chloride (alkyl dimethyl benzyl ammonium chloride), benzethonium chloride New generation: dialkyl dimethyl ammonium halide/carbonate (didecyl dimethyl ammonium chloride/carbonate, octyl decyl dimethyl ammonium chloride, dioctyl dimethyl ammonium bromide, didecyl dimethyl ammonium bicarbonate), dimethyl ethylbenzyl ammonium chloride
Thiazoles	Methylchloroisothiazolinone, methylisothiazolinone

Table 2 Skin irritation, sensitization, and significant skin manifestations of disinfectants

Classification	Examples	Skin irritation	Skin sensitization	Skin manifestations	Effect on skin components
Alcohols	Ethanol	Yes ^{8,12,14}	No ^{18–20}	Dryness, itchiness, burning (at high concentrations)	● Stratum corneum (SC) lipid solubilization, fluidization, and extraction ^{111–115} ● SC protein denaturation ^{112,116}
	Isopropanol	Yes ^{8,12,14}	No ^{18–20}		● Crosslinking with protein (discoloration) ²⁷
Aldehydes	Glutaraldehyde	Yes ^{24,25}	Yes ^{24,25}	Yellow-brown discoloration	
	Polyhexamethylene biguanide hydrochloride (polyhexanide)	No ³⁴	Yes ^{29,34}	Edema, redness, flaking with papules	n.a.
Chlorine and chlorine compounds	Sodium hypochlorite	Yes ^{38,39}	No ⁴⁰	Burning sensation, pain, redness, edema, blisters, tissue necrosis	● SC protein and lipid oxidation ^{117–119}
	Triethylene glycol	No ¹²⁰	No ¹²⁰	n.a.	n.a.
Glycols	1,2-Hexanediol	No ^{121,122}	No ¹²²	n.a.	● SC lipid fluidization and disordering ^{121–123}
	Polyvinylpyrrolidone	No ^{44–49}	No ¹²⁴	Burns with blisters and tissue necrosis (associated with wounds)	n.a.
Iodophors	Iodine	No ⁵⁸	No ⁵⁸	Brown-black discoloration	● Photoreduction on keratin protein (discoloration) ^{59,60}
	Silver ions	No ^{61,125}	No ^{61,125}	Peeling, burning, skin thickening, reversible photosensitivity, contact urticaria, reduced melanin deposition	● Disruption of tight junction and adhesion of keratinocytes ¹²⁶ ● Inhibition of tyrosinase activities of melanocytes ⁷⁴
Metal ions	Citric acid	Yes ^{61,125}	No ^{61,125}		
	Glycolic acid	Yes ^{61,125}	No ^{61,125}		
Fatty acids	Lactic acid	Yes ^{127–129}	No ^{127–129}	n.a.	n.a.
	Caprylic acid (octanoic acid)	Yes ^{127–129}	No ^{127–129}	Skin thickening	● Epidermal cell apoptosis, reduction of keratinocyte proliferation, and Langerhans cells ^{127,129,130} ● SC lipid disordering ¹³¹
Peroxygen compounds	Pelargonic acid (nonanoic acid)	Yes ^{75,78–80}	No ^{75,78–80}	Blanching, edema, peeling, burns (at high concentrations)	● Surfactant action on keratin protein and cell membranes ¹²⁷ ● Hemoglobin oxidation, oxygen-induced vasoconstriction ^{76,132} ● SC protein and lipid oxidation, lipid solubilization
	Hydrogen peroxide	Yes ⁸²	No ⁸²	Burning sensation, itchiness	n.a.
Phenolic compounds	Peroxyacetic acid (peracetic acid)	Yes ¹³³	No ¹³³	Leucoderma	● Inhibition of tyrosinase activities of melanocytes ¹³⁴
	Ortho-phenylphenol	No ¹³⁵	No ¹³⁵	n.a.	● SC lipid fluidization ^{136,137} ● SC protein denaturation and lipid plasticization ¹³⁸ ● Protein denaturation and lipid plasticization ¹³⁸
Anionic surfactants	Thymol	Yes ^{139,140}	No ¹⁴³	Urticaria ^{141,142}	● SC protein denaturation and lipid solubilization ^{144,145}
	Chlorocresol	Yes ¹⁴³	No ¹⁴³	Roughness, erythema	
Cationic surfactants	Dodecylbenzenesulfonic acid	Yes ^{146,147}	No ^{146,147}	Inflammation	● SC lipid solubilization (cholesterols) ^{97,148} ● SC protein denaturation ¹⁴⁹
	Benzalkonium chloride (alkyl dimethyl benzyl ammonium chloride)	Yes ¹⁵⁰	No ¹⁵⁰		
	Benzethonium chloride	Yes ^{101–105}	Yes ^{101–105}	Urticaria, swelling, erythema, itchiness	● SC lipid solubilization (cholesterols) ¹⁵¹
	Didecyl dimethyl ammonium chloride	Yes ^{101–105}	Yes ^{101–105}		

n.a., not available/unknown.

^a Potential due to increased cases.

Table 3 Molecular weight, log *P*, and skin penetration of disinfectants

Classification	Examples	Molecular weight (Da)	Log <i>P</i> ^a	Skin penetration
Alcohols	Ethanol	46.1	-0.16	Yes (low) ^{9,10}
	Isopropanol	60.1	0.25	
Aldehydes	Glutaraldehyde	100.1	-0.27	Yes (low) ^{22,23}
Biguanides	Polyhexamethylene biguanide hydrochloride (polyhexanide)	Variable (average: 1415.0)	-2.39 ³⁴	Yes (low) ²⁸
	Sodium hypochlorite	74.4	0.32	Yes (very low) ³⁸
Chlorine and chlorine compounds	Chlorine dioxide	67.5	0.26	No ⁴²
Glycols	Triethylene glycol	150.2	-1.30	No ¹⁵²
	1,2-Hexanediol	118.2	0.62	
Iodophors	Polyvinylpyrrolidone iodine	365.0	1.36 (iodine)	Yes ⁴³
Metal ions	Silver ions	107.9	-0.73	Yes (low) ⁵⁶
α-Hydroxy acids	Citric acid	192.1	-1.32	Yes ⁶¹⁻⁶⁴
	Glycolic acid	76.1	-1.04	
	Lactic acid	90.1	-0.47	
Fatty acids	Caprylic acid (octanoic acid)	144.2	2.70	Yes ¹²⁸
	Pelargonic acid (nonanoic acid)	158.2	3.14	Yes ¹²⁸
Peroxygen compounds	Hydrogen peroxide	34.0	-0.45	n.a.
	Peroxyacetic acid (peracetic acid)	76.1	-0.30	n.a.
Phenolic compounds	Ortho-phenylphenol	170.2	3.32	Yes ^{84,85,153-156}
	Thymol	150.2	3.43	Yes (very low) ¹³⁸
	Chlorocresol	142.6	2.79	Yes (very low) ¹³⁸
Anionic surfactants	Dodecylbenzenesulfonic acid	326.5	6.56	No ⁹²
Cationic surfactants	Benzalkonium chloride (alkyl dimethyl benzyl ammonium chloride)	Variable (C10: 311.9; C12: 340.0; C14: 368.1; C16: 396.1)	C10: 1.74; C12: 2.63; C14: 3.52; C16: 4.41	Yes ⁹⁹
	Didecyl dimethyl ammonium chloride	362	4.01	Yes ¹⁰⁰

n.a., not available/unknown.

^a Calculated using MarvinSketch program (ChemAxon Ltd., Hungary) unless otherwise specified.

Aldehydes

Glutaraldehyde does not readily penetrate the skin (10% glutaraldehyde: up to ~14%; 0.75% and 7.5% glutaraldehyde: ~0.2%)^{22,23}; however, it is irritating and can cause necrosis at higher concentrations (20%).^{24,25} ACD frequently occurs due to occupational (1% to 2%) and experimental (1% to 10%) exposures.²⁴ This involves a Th2-dominant cytokine expression profile with a higher interleukin-4 (IL-4) over Th1-associated interferon- γ (IFN- γ).²⁶ Yellow-brown skin discoloration has the tanning effect from glutaraldehyde cross-linking of proteinaceous components such as keratin and collagen that alters the protein structure, thus creating yellow-brown discoloration.²⁷

Biguanides

The dermal absorption of polyhexamethylene biguanide hydrochloride (PHMB) or polyhexanide is low (4%).²⁸ ACD is rare (0.5%) with application of 0.4% to 0.5% PHMB, and even at 5% PHMB, the reporting remains insignificant

(0.8%).²⁹ Despite this, ACD is continually reported in recent years and has partial cross-reactivity with other biguanides such as chlorhexidine and polyaminopropylbiguanide.³⁰⁻³³ PHMB is recognized as a moderate-to-strong skin sensitizer at concentrations above 1.2%.³⁴ Anaphylaxis rarely occurs and may be related to wound treatment involving damaged skin.³⁵⁻³⁷

Chlorine and chlorine compounds

The percutaneous penetration for hypochlorites is low and is attributed to its high reactivity, oxidizing, and alkalinity properties when in contact with proteinaceous materials.³⁸ Hypochlorites are nonirritating when diluted (0.1%) but are skin irritants at 5% to 10%.^{38,39} Heat release from an exothermic reaction with water may worsen the reactions.⁴⁰ Other skin manifestations, such as burning sensation, pain, redness, edema, blisters, and necrosis, are known.⁴⁰ Beyond 10%, hypochlorites are corrosive and can cause chemical burns.

Chlorine dioxide (ClO₂) is a highly reactive and unstable chlorine compound. The oxidizing effect on the skin may be similar to hypochlorites but milder even at very high

concentrations considering the rapid degradation.⁴¹ Even though chlorine gas produced can be irritating to the skin, the effect is insignificant, because no dermal uptake occurs with intact human skin.⁴²

Iodophors

Iodophors or polyvinylpyrrolidone (povidone, PVP) iodines (PVP-I) is nonstaining, being relatively less toxic and irritating, compared with iodine. Topical absorption seems to be time dependent.⁴³ ICD (usually 10% PVP-I) sometimes occurs with chemical burns, pain, blistering lesions, and tissue necrosis.^{44–49} Such burns, however, are often observed in damaged skin and/or wounds with prolonged exposure.^{48,50,51} These side effects are associated with the wet condition during application and the continuous release of free iodine (I_2) that act as weak oxidants such as iodine cations (H_2OI^+).⁴⁸ ACD and anaphylactic reactions are seldom reported and mainly may be due to other ingredients such as alcohols and PVP,^{52–55} which can induce IgE-mediated allergic reactions.⁵²

Metal ions

Percutaneous absorption of silver and its nanoparticle forms is usually low in both intact and damaged skin (<4%), because its ionized form does not penetrate the skin readily.^{56,57} ACD is known to occur due to the other ingredients.⁵⁸ Local skin discoloration (brown-black) is occasionally observed and be seen more frequently with topical application to wounds.^{59,60} This is not true argyria (blue-grayish discoloration), which is more long-lasting and common after chronic exposure through inhalation or oral ingestion.⁵⁹

α -Hydroxy acids

α -Hydroxy acids (AHAs), including citric acid (CA), glycolic acid (GA), and lactic acid (LA), can penetrate the skin, but the dermal absorption is dependent on pH, concentration, and time.^{61–64} Burning, dermatitis, skin peeling, itching, and moderate sunburns are frequently reported at a concentration $\leq 10\%$ or a pH ≥ 3.5 .⁶⁵ This can be related to the expression of proinflammatory cytokines, such as tumor necrosis factor- α (TNF- α) and IL-1 α .⁶⁶ An increased epidermal and dermal thickness is common at higher concentrations (CA and GA: 20% to 40%; LA: 12%).^{67–70} AHA may also induce reversible skin photosensitivity and contact urticaria.^{61,71,72} CA and GA ($\geq 3\%$) can induce apoptosis of keratinocytes that enhances photodamage to the skin.⁷³ AHA may also decrease melanin deposition in the skin *in vivo*.^{69,74} AHA at lower concentrations has none of these effects and is highly useful in dermatologic practice.

Peroxygen compounds

Dermal penetration of hydrogen peroxide (H_2O_2) remains unknown due to the rapid degradation into oxygen and water,

especially when in contact with organic materials.⁷⁵ A transient skin blanching, usually benign, is often detected.⁷⁶ In addition, vacuolar eruption due to oxygen bubble formation in the skin (gas embolism) is a unique clinical manifestation from an exposure of up to 35% H_2O_2 .⁷⁷ H_2O_2 is usually nonirritating at a low concentration ($\leq 10\%$) despite being a strong oxidizing antiseptic.^{75,78–80} At 35%, H_2O_2 can cause reversible erythema and edema but irreversible skin desquamation. With a concentration of more than 50%, chemical burns are usually noticed. Prolonged exposure may produce the same reactions at a lower concentration.

Skin irritation, erythema, scaling, and roughness may occur with repeated application of 0.1% to 0.2% of peracetic acid (PA).⁸¹ Acute skin irritation has been observed at 0.5% to 3%.⁸² A regular spray, using 0.2% to 0.5% PA during the SARS outbreak in 2002 to 2003 created multiple health hazards, including skin irritation, burning, and itching, lasting up to 5 hours.⁸³ The cause may be due to the excellent lipid solubility of PA and its strong oxidative disruption on the skin lipids and keratin protein.

Phenolic compounds

Phenol and its derivative, especially ortho-phenylphenol (OPP) or biphenyl-2-ol and ortho-benzyl-para-chlorophenol (OBPCP), have excellent skin-penetrating power.^{84,85} Skin reactions can develop with short contact. ACD related to OPP and OBPCP may occur even at low concentrations (0.1%).^{86–88} Chemical burns and digital tip gangrene have occurred after persistent exposure to 0.5% halogenated phenol; the actual causative compound was not stated.⁸⁹ Depigmentation or leukoderma is another clinical concern when applying OPP and OBPCP (1%),^{90,91} although the depigmentation is reversible but with the repigmentation process taking upward to a year or more.

Surfactants

Anionic surfactants

Sodium dodecylbenzenesulfonate does not readily penetrate the skin, but penetration may happen due to prolonged contact.⁹² Repeated application (1%) can result in moderate to severe erythema and skin roughness.^{92–96}

Cationic surfactants

(quaternary ammonium compounds)

Benzalkonium chloride (BAC) can penetrate the skin and induce skin irritation and inflammation at low concentrations (0.1%).^{97,98} ACD is rare.⁹⁹ Newer generations of quaternary ammonium compounds (QAC), dialkyl QAC, such as didecyl dimethyl ammonium chloride (DDAC), have poor cutaneous *in vitro*.¹⁰⁰ ACD has been reported at very low concentrations (0.01%), and immediate hypersensitivity is possible.^{101–105} Urticaria, swelling, erythema, and itchiness can be found at higher concentrations (1% to 10%).^{104,106} DDAC may

produce mixed hypersensitivity that induces both IgE- and T-cell-mediated responses.^{107–109} DDAC can be a skin irritant and sensitizer, probably stronger than BAC.

Safety preventive measures

Although the use of disinfectants is inevitable, it is crucial to consider the following points to minimize or avoid any potential dermatologic reactions:

- Damaged skin is prone to adverse reactions from a direct absorption of disinfectants, and extra care should be given to avoid contact with disinfectants.
- While multiple disinfectants may be used together or formulated as a single product to achieve synergistic effects, an enhanced adverse effect is expected.
- Whenever dermatitis is known, disinfectants that are weak or nonirritants and sensitizers should be prioritized. Patch testing may be considered. It is important to avoid using disinfectants from a similar class that is known to be allergic to the users in consideration of a potential cross-reactivity.
- It is necessary to use protective garments during handling to avoid direct contact from spillage. Even with regular use of protective attires, unnoticeable punctures in the gloves on multiple uses and the handling of disinfected surfaces can expose users to contamination. Possible interactions of disinfectants with protective garments may occur; for example, glutaraldehyde at 2% to 3.4% may penetrate latex gloves after 45 min, and thus butyl rubber and nitrile rubber gloves are recommended.¹¹⁰
- Emphasis is given only on the dermatologic reactions in this review, but the exposure through other manners such as ocular route and inhalation is often significant and most probably toxic. For instance, chlorine compounds are known to emit chlorine gas during preparation and application. The exposure to the eyes is thus high and toxic.

Conclusions

The dermatologic events are usually, but not always, related to prolonged exposure and contact with concentrated disinfectants. Many dermatologic adverse events remain unreported. Some skin reactions, especially sensitization, can develop for compounds currently known to be a nonirritant or sensitizer.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. World Health Organization. *WHO virtual press conference on COVID-19*. March 11, 2020 https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2.
2. Lachapelle JM. A comparison of the irritant and allergenic properties of antiseptics. *Eur J Dermatol* 2014;24:3-9.
3. Lee HY, Stieger M, Yawalkar N, et al. Cytokines and chemokines in irritant contact dermatitis. *Mediat Inflamm* 2013;2013:916497.
4. Sebastiani S, Albanesi C, De Pità O, et al. The role of chemokines in allergic contact dermatitis. *Arch Dermatol Res* 2002;293:552-559.
5. Nosbaum A, Nicolas J-F. Irritant versus allergic contact dermatitis: an etiopathological approach. In: Alikhan A, Lachapelle J-M, Maibach HI, eds. *Textbook of Hand Eczema*. Berlin: Springer; 2014. p. 69-74.
6. European Chemicals Agency. *COVID-19 Lists of Disinfectant Active Substances and Products*. European Chemicals Agency: Helsinki. 2020 <https://data.europa.eu/euodp/en/data/dataset/biocidal-products-lists-of-disinfectant-active-substances-and-products>.
7. US Environmental Protection Agency. *List N: Disinfectants for Use Against SARS-CoV-2*. Washington, DC: US Environmental Protection Agency. 2020 <https://www.epa.gov/pesticide-registration/list-n-disinfectants-coronavirus-covid-19>.
8. World Health Organization. *WHO Guidelines on Hand Hygiene in Health Care*. Geneva: WHO Press. 2009.
9. Blank IH. Penetration of low-molecular-weight alcohols into skin. I. Effect of concentration of alcohol and type of vehicle. *J Invest Dermatol* 1964;43:415-420.
10. Pendlington RU, Whittle E, Robinson JA, et al. Fate of ethanol topically applied to skin. *Food Chem Toxicol* 2001;39:169-174.
11. Kramer A, Below H, Bieber N, et al. Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans. *BMC Infect Dis* 2007;7:117.
12. Lachenmeier DW. Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity. *J Occup Med Toxicol* 2008;3:26.
13. Löffler H, Kampf G. Hand disinfection: how irritant are alcohols? *J Hosp Infect* 2008;70:44-48.
14. de Haan P, Meester HHM, Bruynzeel DP. Irritancy of alcohols. In: Van der Valk P, Maibach H, eds. *The Irritant Contact Dermatitis Syndrome*. New York: CR Press; 1996. p. 65-70.
15. Goh CF, Mohamed Ahmed AHA. How to make hand sanitiser gel. *Commun Eye Health J* 2020;33:16.
16. Mohamed Ahmed AHA, Goh CF. How to make hand sanitiser/hand rub. *Commun Eye Health J* 2020;33:14-15.
17. Berardi A, Perinelli DR, Merchant HA, et al. Hand sanitisers amid CoViD-19: a critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand. *Int J Pharm* 2020;584:119431.
18. Pecquet C, Pradalier A, Dry J. Allergic contact dermatitis from ethanol in a transdermal estradiol patch. *Contact Dermat* 1992;27:275.
19. Barbaud A, Trechot P, Reichert-Penetrat S, et al. Contact dermatitis due to ethyl alcohol: how to perform patch tests? *Ann Dermatol Venerol* 2000;1339:469-549.
20. Cimiotti JP, Marmur ES, Nesin M, et al. Adverse reactions associated with an alcohol-based hand antiseptic among nurses in a neonatal intensive care unit. *Am J Infect Control* 2003;31:43-48.
21. Ophaswongse S, Maibach HI. Alcohol dermatitis: allergic contact dermatitis and contact urticaria syndrome. *Contact Dermat* 1994;30:1-6.
22. Reifenhath WG, Prystowsky SD, Nonomura JH, et al. Topical glutaraldehyde-percutaneous penetration and skin irritation. *Arch Dermatol Res* 1985;277:242-244.
23. Frantz SW, Beskitt JL, Tallant MJ, et al. Glutaraldehyde: species comparisons of *in vitro* skin penetration. *J Toxicol Cutan Ocul Toxicol* 1993;12:349-361.

24. Takigawa T, Endo Y. Effects of glutaraldehyde exposure on human health. *J Occup Health* 2006;48:75-87.
25. Beauchamp RO, St Clair MBG, Fennell TR, et al. A critical review of the toxicology of glutaraldehyde. *Crit Rev Toxicol* 1992;22:143-174.
26. van Triel JJ, van Bree BWJ, Roberts DW, et al. The respiratory allergen glutaraldehyde in the local lymph node assay: sensitization by skin exposure, but not by inhalation. *Toxicology* 2011;279:115-122.
27. Ruijgrok JM, de Wijn JR, Boon ME. Glutaraldehyde crosslinking of collagen: effects of time, temperature, concentration and presoaking as measured by shrinkage temperature. *Clin Mater* 1994;17:23-27.
28. Scientific Committee on Consumer Safety. *Opinion on Polyaminopropyl Biguanide (PHMB) - Submission III*. Luxembourg: European Commission. 2017.
29. Schnuch A, Geier J, Uter W, et al. The biocide polyhexamethylene biguanide remains an uncommon contact allergen. *Contact Dermat* 2007;56:235-239.
30. Aerts O, Smeets J, Adriaenssens K, et al. Contact allergy to biguanides might explain cases of unresolved eyelid dermatitis. *J Eur Acad Dermatol Venereol* 2015;29:2064-2065.
31. Pummi K, Kemppi E, Lammintausta K. Occupational sensitization to polyhexamethylene guanidine hydrochloride in a non-alcoholic hand rub. *Contact Dermat* 2012;66:348-349.
32. Leysen J, Goossens A, Lambert J, et al. Polyhexamethylene biguanide is a relevant sensitizer in wet wipes. *Contact Dermat* 2014;70:323-325.
33. Pastor-Nieto M-A, González-Muñoz P, Pérez-Mesonero R, et al. Allergic contact dermatitis caused by poly(hexamethylene) biguanide hydrochloride in contact lens care solutions. *Contact Dermat* 2017;76:373-376.
34. *Assessment Report - Polyhexamethylene Biguanide (Mn = 1415; PDI = 4.7)*. Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products. France: European Commission. 2017.
35. Schunter JA, Stöcker B, Brehler R. A case of severe anaphylaxis to polyhexanide: cross-reactivity between biguanide antiseptics. *Int Arch Allergy Immunol* 2017;173:233-236.
36. Olivieri J, Eigenmann PA, Hauser C. Severe anaphylaxis to a new disinfectant: polyhexanide, a chlorhexidine polymer. *Schweiz Med Wochenschr* 1998;128:1508-1511.
37. Kautz O, Schumann H, Degerbeck F, et al. Severe anaphylaxis to the antiseptic polyhexanide. *Allergy* 2010;65:1068-1070.
38. *Assessment Report - Active Chlorine Released from Sodium Hypochlorite*. Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products. Italy: Europe Commission. 2017.
39. Bruch M. Toxicity and safety of topical sodium hypochlorite. *Contrib Nephrol* 2007;154:24-38.
40. Slaughter RJ, Watts M, Vale JA, et al. The clinical toxicology of sodium hypochlorite. *Clin Toxicol* 2019;57:303-311.
41. Toxicological Profile for Chlorine Dioxide and Chlorite. Atlanta: US Agency for Toxic Substances and Disease Registry. 2004.
42. Gaskin S, Pisaniello D, Edwards JW, et al. Chlorine and hydrogen cyanide gas interactions with human skin: *in vitro* studies to inform skin permeation and decontamination in HAZMAT incidents. *J Hazard Mater* 2013;262:759-765.
43. Nesvadbova M, Crosera M, Maina G, et al. Povidone iodine skin absorption: an *ex-vivo* study. *Toxicol Lett* 2015;235:155-160.
44. Liu FC, Liou JT, Hui YL, et al. Chemical burn caused by povidone-iodine alcohol solution—a case report. *Acta Anaesthesiol Sin* 2003;41:93-96.
45. Nahlieli O, Baruchin AM, Levi D, et al. Povidone-iodine related burns. *Burns* 2001;27:185-188.
46. Chiang YC, Lin TS, Yeh MC. Povidone-iodine-related burn under the tourniquet of a child—a case report and literature review. *J Plast Reconstr Aesthet Surg* 2011;64:412-415.
47. Murthy MB, Krishnamurthy B. Severe irritant contact dermatitis induced by povidone iodine solution. *Indian J Pharmacol* 2009;41:199-200.
48. Iijima S, Kuramochi M. Investigation of irritant skin reaction by 10% povidone-iodine solution after surgery. *Dermatology (Basel, Switzerland)* 2002;204(suppl 1):103-108.
49. Rees A, Sherrod Q, Young L. Chemical burn from povidone-iodine: case and review. *J Drugs Dermatol* 2011;10:414-417.
50. Kambara Y, Hiramatsu K, Kato T, et al. Randomized clinical trial of single skin sterilization with a povidone-iodine applicator versus conventional skin sterilization in abdominal surgery. *BJS Open* 2019;3:282-287.
51. Borrego L, Hernández N, Hernández Z, et al. Povidone-iodine induced post-surgical irritant contact dermatitis localized outside of the surgical incision area. Report of 27 cases and a literature review. *Int J Dermatol* 2016;55:540-545.
52. Adachi A, Fukunaga A, Hayashi K, et al. Anaphylaxis to polyvinylpyrrolidone after vaginal application of povidone-iodine. *Contact Dermat* 2003;48:133-136.
53. Waran K, Munsick R. Anaphylaxis from povidone-iodine. *Lancet* 1995;345:1506.
54. Marks Jr JG. Allergic contact dermatitis to povidone-iodine. *J Am Acad Dermatol* 1982;6:473-475.
55. Niedner R. Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. *Dermatology* 1997;195(suppl 2):89-92.
56. Lansdown ABG. *Silver in Healthcare: Its Antimicrobial Efficacy and Safety in Use*. Cambridge, UK: Royal Society of Chemistry. 2010.
57. Larese FF, D'Agostin F, Crosera M, et al. Human skin penetration of silver nanoparticles through intact and damaged skin. *Toxicology* 2009;255:33-37.
58. Group A, Lea A. Contact dermatitis with a highlight on silver: a review. *Wounds* 2010;22:311-315.
59. Lansdown ABG. A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. *Adv Pharmacol Sci* 2010;2010:910686.
60. Isak V, Beerli T, Cozzio A, et al. A rare case of localized argyria on the face. *Case Rep Dermatol* 2019;11:23-27.
61. Andersen FA. Final report on the safety assessment of glycolic acid, ammonium, calcium, potassium, and sodium glycolates, methyl, ethyl, propyl, and butyl glycolates, and lactic acid, ammonium, calcium, potassium, sodium, and tea-lactates, methyl, ethyl, isopropyl, and butyl lactates, and lauryl, myristyl, and cetyl lactates. *Int J Toxicol* 1998;17:1-241.
62. Jiang M, Qureshi SA. Assessment of *in vitro* percutaneous absorption of glycolic acid through human skin sections using a flow-through diffusion cell system. *J Dermatol Sci* 1998;18:181-188.
63. Kraeling M, Bronaugh R. *In vitro* percutaneous absorption of alpha hydroxy acids in human skin. *J Cosmet Sci* 1997;48:187-197.
64. Okuda M, Donahue DA, Kaufman LE, et al. Negligible penetration of incidental amounts of alpha-hydroxy acid from rinse-off personal care products in human skin using an *in vitro* static diffusion cell model. *Toxicol in Vitro* 2011;25:2041-2047.
65. US Food and Drug Agency. *Guidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids*. College Park, MD: U.S Food and Drug Agency. 2005.
66. Jeong SK, Ko JY, Seo JT, et al. Stimulation of epidermal calcium gradient loss and increase in TNF- α and IL-1 α expressions by glycolic acid in murine epidermis. *Exp Dermatol* 2005;14:571-579.
67. Bernstein EF, Underbill CB, Lakkakorpi J, et al. Citric acid increases viable epidermal thickness and glycosaminoglycan content of sun-damaged skin. *Dermatol Surg* 1997;23:689-694.
68. Bernstein EF, Lee J, Brown DB, et al. Glycolic acid treatment increases type I collagen mRNA and hyaluronic acid content of human skin. *Dermatol Surg* 2001;27:429-433.

69. Yamamoto Y, Uede K, Yonei N, et al. Effects of alpha-hydroxy acids on the human skin of Japanese subjects: the rationale for chemical peeling. *J Dermatol* 2006;33:16-22.
70. Smith WP. Epidermal and dermal effects of topical lactic acid. *J Am Acad Dermatol* 1996;35:388-391.
71. Kaidbey K, Sutherland B, Bennett P, et al. Topical glycolic acid enhances photodamage by ultraviolet light. *Photodermatol Photoimmunol Photomed* 2003;19:21-27.
72. Vishal B, Rao SS, Pavithra S, et al. Contact urticaria to glycolic acid peel. *J Cutan Aesthet Surg* 2012;5:58-59.
73. Tang S-C, Yang J-H. Dual effects of alpha-hydroxy acids on the skin. *Molecules* 2018;23:863.
74. Usuki A, Ohashi A, Sato H, et al. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. *Exp Dermatol* 2003;12:43-50.
75. *Assessment Report - Hydrogen Peroxide*. Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products. Finland: European Commission. 2015.
76. Chan HP, Maibach HI. Hydrogen peroxide, blanching, and skin: an overview. *Cutan Ocul Toxicol* 2008;27:307-309.
77. Izu K, Yamamoto O, Asahi M. Occupational skin injury by hydrogen peroxide. *Dermatology* 2000;201:61-64.
78. European Union Risk Assessment Report - Hydrogen Peroxide. Helsinki: European Communities. 2003.
79. Bito T, Izu K, Tokura Y. Evaluation of toxicity and Stat3 activation induced by hydrogen peroxide exposure to the skin in healthy individuals. *J Dermatol Sci* 2010;58:157-159.
80. Murphy EC, Friedman AJ. Hydrogen peroxide and cutaneous biology: translational applications, benefits, and risks. *J Am Acad Dermatol* 2019;81:1379-1386.
81. Peracetic acid [MAK value documentation, 1996]. The MAK-Collection for Occupational Health and Safety. Weinheim, Germany: Wiley; 1996. p. 230-239.
82. Peracetic Acid Acute Exposure Guideline Levels Acute Exposure Guideline Levels for Selected Airborne Chemicals by National Research Council (US) Committee on Acute Exposure Guideline Levels. Washington, DC: National Academies Press. 2010:327-367.
83. You Y, Bai Z, Yan L, et al. Peracetic acid exposure assessment during outbreak of SARS in Tianjin, China [Abstract]. *Epidemiology* 2006;17: S217-S218.
84. Roberts MS, Anderson RA. The percutaneous absorption of phenolic compounds: the effect of vehicles on the penetration of phenol. *J Pharm Pharmacol* 1975;27:599-605.
85. Hinz RS, Lorence CR, Hodson CD, et al. Percutaneous penetration of para-substituted phenols in vitro. *Fundam Appl Toxicol* 1991;17: 575-583.
86. Sonnex TS, Rycroft RJG. Allergic contact dermatitis from orthobenzyl parachlorophenol in a drinking glass cleaner. *Contact Dermat* 1986;14: 247-248.
87. Adams RM. Allergic contact dermatitis due to o-phenylphenol. *Contact Dermat* 1981;7:332.
88. Estlander T, Kanerva L, Jolanki R. Occupational skin sensitization to the antimicrobials ortho-benzyl para-chlorophenol and ampholyte 103 G. In: Frosch P, Dooms-Goossens A, Lachapelle JM, et al, eds. Current Topics in Contact Dermatitis. Berlin: Springer; 1989. p. 88-91.
89. DeBono R, Laitung G. Phenolic household disinfectants—further precautions required. *Burns* 1997;23:182-185.
90. Kahn G. Depigmentation caused by phenolic detergent germicides. *Arch Dermatol* 1970;102:177-187.
91. Arundell FD. San Francisco Dermatological Society. *Arch Dermatol* 1973;108:848-849.
92. *Final report on the safety assessment of sodium dodecylbenzenesulfonate/TEA-dodecylbenzenesulfonate/ sodium decylbenzenesulfonate*. *J Am Coll Toxicol* 1993;12:279-309.
93. Prottey C, Ferguson T. Factors which determine the skin irritation potential of soaps and detergents. *J Soc Cosmet Chem* 1975;26:29-46.
94. Harrold S. Denaturation of epidermal keratin by surface active agents. *J Invest Dermatol* 1959;32:581-588.
95. Van Scott EJ, Lyon JB. A chemical measure of the effect of soaps and detergents on the skin. *J Invest Dermatol* 1953;21:199-203.
96. Imokawa G, Sumura K, Katsumi M. Study on skin roughness caused by surfactants: II. Correlation between protein denaturation and skin roughness. *J Am Oil Chem Soc* 1975;52:484-489.
97. Aki H, Koizumi E, Okamoto Y, et al. Interaction of stratum corneum components with benzalkonium chloride. Isothermal Titration Calorimetric Study. *J Therm Anal Calorimetry* 2001;64:293-297.
98. Basketter DA, Marriott M, Gilmour NJ, et al. Strong irritants masquerading as skin allergens: the case of benzalkonium chloride. *Contact Dermat* 2004;50:213-217.
99. Wentworth AB, Yiannias JA, Davis MDP, et al. Benzalkonium chloride: a known irritant and novel allergen. *Dermatitis* 2016;27:14-20.
100. Buist HE, de Heer C, van Burgsteden JA, et al. Dermatokinetics of didecylmethylammonium chloride and the influence of some commercial biocidal formulations on its dermal absorption in vitro. *Regul Toxicol Pharmacol* 2007;48:87-92.
101. Dejobert Y, Martin P, Piette E, et al. Contact dermatitis from didecylmethylammonium chloride and bis-(aminopropyl)-laurylamine in a detergent-disinfectant used in hospital. *Contact Dermat* 1997;37:95.
102. Mowitz M, Pontén A. Foot dermatitis caused by didecylmethylammonium chloride in a shoe refresher spray. *Contact Dermat* 2015;73:374-376.
103. Geier J, Lessmann H, Cevik N, et al. Patch testing with didecylmethylammonium chloride. *Contact Dermat* 2016;74:374-376.
104. Houtappel M, Bruijnzeel-Koomen CAFM, Röckmann H. Immediate-type allergy by occupational exposure to didecyl dimethyl ammonium chloride. *Contact Dermat* 2008;59:116-117.
105. Dibo M, Brasch J. Occupational allergic contact dermatitis from N,N-bis (3-aminopropyl)dodecylamine and dimethyldodecylammonium chloride in 2 hospital staff. *Contact Dermat* 2001;45:40.
106. Ruiz Oropeza A, Fischer Friis U, Duus Johansen J. Occupational contact urticaria caused by didecyl dimethyl ammonium chloride. *Contact Dermat* 2011;64:297-298.
107. Shane HL, Lukomska E, Stefaniak AB, et al. Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecylmethylammonium bromide. *J Immunotoxicol* 2017;14:204-214.
108. Anderson SE, Shane H, Long C, et al. Evaluation of the irritancy and hypersensitivity potential following topical application of didecylmethylammonium chloride. *J Immunotoxicol* 2016;13:557-566.
109. Shane HL, Lukomska E, Kashon ML, et al. Topical application of the quaternary ammonium compound didecylmethylammonium chloride activates type 2 innate lymphoid cells and initiates a mixed-type allergic response. *Toxicol Sci* 2019;168:508-518.
110. Jordan SL, Stowers MF, Trawick EG, et al. Glutaraldehyde permeation: choosing the proper glove. *Am J Infect Control* 1996;24:67-69.
111. Kownatzki E. Hand hygiene and skin health. *J Hosp Infect* 2003;55:239-245.
112. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, et al. Percutaneous absorption enhancement of an ionic molecule by ethanol-water systems in human skin. *Pharm Res* 1990;7:762-766.
113. Bommannan D, Potts RO, Guy RH. Examination of the effect of ethanol on human stratum corneum *in vivo* using infrared spectroscopy. *J Control Release* 1991;16:299-304.

114. Berner B, Juang R-H, Mazzenga GC. Ethanol and water sorption into stratum corneum and model systems. *J Pharm Sci* 1989;78:472-476.
115. Brinkmann I, Müller-Goymann CC. Role of isopropyl myristate, isopropyl alcohol and a combination of both in hydrocortisone permeation across the human stratum corneum. *Skin Pharmacol Physiol* 2003;16:393-404.
116. Goates CY, Knutson K. Enhanced permeation of polar compounds through human epidermis. I. Permeability and membrane structural changes in the presence of short chain alcohols. *Biochim Biophys Acta Biomembr* 1994;1195:169-179.
117. Hawkins CL, Pattison DI, Davies MJ. Hypochlorite-induced oxidation of amino acids, peptides and proteins. *Amino Acids* 2003;25:259-274.
118. Schröter J, Schiller J. Chlorinated phospholipids and fatty acids: (patho) physiological relevance, potential toxicity, and analysis of lipid chlorohydrins. *Oxidative Med Cell Longev* 2016;2016:8386362.
119. Thiele JJ, Hsieh SN, Briviba K, et al. Protein oxidation in human stratum corneum: susceptibility of keratins to oxidation *in vitro* and presence of a keratin oxidation gradient *in vivo*. *J Invest Dermatol* 1999;113:335-339.
120. Triethylene glycol [MAK value documentation, 2007]. The MAK-Collection for Occupational Health and Safety. Weinheim, Germany: Wiley; 2007. p. 1-25.
121. Lee E, An S, Cho SA, et al. The influence of alkane chain length on the skin irritation potential of 1,2-alkanediols. *Int J Cosmet Sci* 2011;33:421-425.
122. Johnson W, Bergfeld WF, Belsito DV, et al. Safety assessment of 1,2-glycols as used in cosmetics. *Int J Toxicol* 2012;31:147S-168S.
123. Warner KS, Li SK, Higuchi WI. Influences of alkyl group chain length and polar head group on chemical skin permeation enhancement. *J Pharm Sci* 2001;90:1143-1153.
124. Lachapelle JM. Allergic contact dermatitis from povidone-iodine: a re-evaluation study. *Contact Dermat* 2005;52:9-10.
125. Fiume MM, Heldreth BA, Bergfeld WF, et al. Safety assessment of citric acid, inorganic citrate salts, and alkyl citrate esters as used in cosmetics. *Int J Toxicol* 2014;33:16s-46s.
126. Wang X. A theory for the mechanism of action of the alpha-hydroxy acids applied to the skin. *Med Hypotheses* 1999;53:380-382.
127. Wahlberg JE, Lindberg M. Nonanoic acid - an experimental irritant. *Contact Dermat* 2003;49:117-123.
128. Kellum RE. Acne vulgaris: studies in pathogenesis: relative irritancy of free fatty acids from C2 to C16. *Arch Dermatol* 1968;97:722-726.
129. Johnson W, Heldreth Bart, et al. Final report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Pelargonic Acid (Nonanoic Acid) and Nonanoate Esters. *Int J Toxicol* 2011;30:228S-269S.
130. Forsey RJ, Shahidullah H, Sands C, et al. Epidermal Langerhans cell apoptosis is induced *in vivo* by nonanoic acid but not by sodium lauryl sulphate. *Br J Dermatol* 1998;139:453-461.
131. Tanojo H, Bouwstra JA, Junginger HE, et al. *In vitro* human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies. *Pharm Res* 1997;14:42-49.
132. Zonios G, Dimou A, Galaris D. Probing skin interaction with hydrogen peroxide using diffuse reflectance spectroscopy. *Phys Med Biol* 2007;53:269-278.
133. Scientific Committee on Consumer Safety. *Opinion on o-Phenylphenol, Sodium o-Phenylphenate and Potassium o-Phenylphenate*. Luxembourg: European Commission. 2015.
134. McGuire J, Hendee J. Biochemical basis for depigmentation of skin by phenolic germicides. *J Invest Dermatol* 1971;57:256-261.
135. Tisserand R, Young R. Toxicity. In: Tisserand R, Young R, eds. *Essential Oil Safety*. 2nd ed. St. Louis: Churchill Livingstone; 2014. p. 23-38.
136. Chantasarit D, Pongjanyakul T, Higuchi WI, et al. Effects of oxygen-containing terpenes as skin permeation enhancers on the lipoidal pathways of human epidermal membrane. *J Pharm Sci* 2009;98:3617-3632.
137. El-Kattan AF, Asbill CS, Michniak BB. The effect of terpene enhancer lipophilicity on the percutaneous permeation of hydrocortisone formulated in HPMC gel systems. *Int J Pharm* 2000;198:179-189.
138. Roberts MS, Anderson RA, Swarbrick J. Permeability of human epidermis to phenolic compounds. *J Pharm Pharmacol* 1977;29:677-683.
139. *Final report on the safety assessment of p-chloro-m-cresol* *Int J Toxicol* 1997;16:235-268.
140. Gotter B, Faubel W, Neubert RHH. FTIR microscopy and confocal Raman microscopy for studying lateral drug diffusion from a semisolid formulation. *Eur J Pharm Biopharm* 2010;74:14-20.
141. Freitas JP, Brandão FM. Contact urticaria to chlorocresol. *Contact Dermat* 1986;15:252.
142. Mehrtens SH, Reckling C. Contact urticaria with anaphylaxis caused by chlorocresol, chloroxylenol, and thiourea. *Contact Dermat* 2019;80:311-313.
143. Becker LC, Bergfeld WF, Belsito DV, et al. Amended safety assessment of dodecylbenzenesulfonate, decylbenzenesulfonate, and tridecylbenzenesulfonate salts as used in cosmetics. *Int J Toxicol* 2010;29:288S-305S.
144. Bartnik F, Künstler K. Biological effects, toxicology and human safety. In: Falbe J, ed. *Surfactants in Consumer Products*. Berlin: Springer-Verlag; 1987. p. 475-503.
145. Froebe CL, Simion FA, Rhein LD, et al. Stratum corneum lipid removal by surfactants: relation to *in vivo* irritation. *Dermatologica* 1990;181:277-283.
146. Uter W, Lessmann H, Geier J, et al. Is the irritant benzalkonium chloride a contact allergen? A contribution to the ongoing debate from a clinical perspective. *Contact Dermat* 2008;58:359-363.
147. Fuchs T, Meinert A, Aberer W, et al. Benzalkonium chloride—a relevant contact allergen or irritant? Results of a multicenter study of the German Contact Allergy Group. *Hautarzt* 1993;44:699-702.
148. Aki H. Interaction of antiseptic compounds with intercellular lipids of stratum corneum. *J Therm Anal Calorimetry* 2002;68:553-560.
149. Kushla GP, Zatz JL. Correlation of water and lidocaine flux enhancement by cationic surfactants *in vitro*. *J Pharm Sci* 1991;80:1079-1083.
150. Opinion of the Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumers Concerning Benzethonium Chloride. European Commission. 2002.
151. Buist HE, van de Sandt JJ, van Burgsteden JA, et al. Effects of single and repeated exposure to biocidal active substances on the barrier function of the skin *in vitro*. *Regul Toxicol Pharmacol* 2005;43:76-84.
152. Lester Jr W, Kaye S, Robertson OH, et al. Factors of importance in the use of triethylene glycol vapor for aerial disinfection. *Am J Public Health Nations Health* 1950;40:813-820.
153. Bartels MJ, McNett DA, Timchalk C, et al. Comparative metabolism of ortho-phenylphenol in mouse, rat and man. *Xenobiotica* 1998;28:579-594.
154. Cnubben NHP, Elliott GR, Hakkert BC, et al. Comparative *in vitro-in vivo* percutaneous penetration of the fungicide ortho-phenylphenol. *Regul Toxicol Pharmacol* 2002;35:198-208.
155. Selim S. *A Single Dose Open Label Study to Investigate the Absorption and Excretion of 14c/13c-Labeled Orthophenylphenol Formulation After Dermal Application to Healthy Volunteers*. Assen, The Netherlands: Pharma Bio-Research Clinics Bv. 1996.
156. Timchalk C, Selim S, Sangha G, et al. The pharmacokinetics and metabolism of 14C/13C-labeled ortho-phenylphenol formation following dermal application to human volunteers. *Hum Exp Toxicol* 1998;17:411-417.